Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty‐six‐week phase 3 open‐label study

Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty‐six‐week phase 3 open‐label study

This phase 3 multicenter study, including 26‐week treatment and extension periods, evaluated the efficacy and safety of adalimumab in Japanese patients with active ulcers due to pyoderma gangrenosum. Patients received adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg every week starting a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of dermatology 2020-12, Vol.47 (12), p.1383-1390
Hauptverfasser: Yamasaki, Kenshi, Yamanaka, Keiichi, Zhao, Yiwei, Iwano, Shunsuke, Takei, Keiko, Suzuki, Koji, Yamamoto, Toshiyuki
Format: Artikel
Sprache:eng
Schlagworte:
adalimumab
Adalimumab - therapeutic use
Clinical outcomes
Clinical trials
Humans
Immunotherapy
Japan
Japanese patient
Monoclonal antibodies
Original
Patient safety
Pyoderma
Pyoderma gangrenosum
Pyoderma Gangrenosum - drug therapy
Quality of life
Skin diseases
skin ulcer
TNF inhibitors
Treatment Outcome
tumor necrosis factor‐α
Ulcer
Ulcers
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This phase 3 multicenter study, including 26‐week treatment and extension periods, evaluated the efficacy and safety of adalimumab in Japanese patients with active ulcers due to pyoderma gangrenosum. Patients received adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg every week starting at week 4. Of the 22 enrolled patients, 12 (54.5%, P 
ISSN:0385-2407
1346-8138
DOI:10.1111/1346-8138.15533